Add-on Ezetimibe Reduces Small Dense Low-Density Lipoprotein Cholesterol Levels Without Affecting Absorption of Eicosapentaenoic Acid in Patients with Coronary Artery Disease: A Pilot Study

作者：Kubo Motoki; Miyoshi Toru^*; Kimura Tomonari; Noda Yoko; Kohno Kunihisa; Nakamura Kazufumi; Morita Hiroshi; Ito Hiroshi

来源：American Journal of Cardiovascular Drugs, 2014, 14(5): 387-392.

DOI：10.1007/s40256-014-0082-3

Residual risk of cardiovascular disease from increased small dense low-density lipoprotein (sdLDL)-cholesterol levels and low n-3 polyunsaturated fatty acid (PUFA) levels is a considerable therapeutic issue. The purpose of this study was to evaluate the effect of ezetimibe as an add-on to statins and supplemental eicosapentaenoic acid (EPA) on sdLDL cholesterol and absorption of EPA in patients with coronary artery disease.
The study population consisted of ten male patients who were concurrently receiving statins and EPA 1,800 mg/day. Serum lipids and PUFAs, including EPA and arachidonic acid, were measured in blood samples collected before ezetimibe (baseline), 4 weeks after starting 10-mg/day ezetimibe, and 4 weeks after discontinuing ezetimibe.
Ezetimibe significantly decreased sdLDL-cholesterol levels after 4 weeks of treatment (baseline 35 +/- A 13 mg/dl; treatment 27 +/- A 9 mg/dl), but the levels returned to baseline after discontinuation of ezetimibe (37 +/- A 13 mg/dl). The concentration of EPA did not significantly change during the study.
Ezetimibe shows great promise as an add-on therapy to statins to reduce sdLDL-cholesterol-related residual risk of cardiovascular disease without affecting absorption of supplemental EPA in patients with coronary artery disease.

• 出版日期2014-10